Saudi Chemical acquires prescription rights for Cialis in Saudi Arabia

05/04/2022 Argaam
Saudi Chemical Holding logo

Saudi Chemical Holding logo

Saudi Chemical Holding Co. (SCHC) completed the agreement to acquire all prescription rights of Cialis in Saudi Arabia from Eli Lilly, following the approvals from the relevant government authorities.

 

In a statement to Tadawul, SCHC said the acquisition was based on the agreement signed on Dec. 27, 2021.

 

Through this acquisition, AJA Pharmaceutical Industries (AJA Pharma), a subsidiary of SCCH, would be the manufacturer and supplier for Cialis in the Saudi market. Cialis revenues in Saudi Arabia reached around SAR 100 million ($26.7 million) during 2021.

 

The acquisition is expected to have a positive impact on SCHC’s revenues, which will be announced later.

 

Cialis is used to treat men with erectile dysfunction and used to treat the signs and symptoms of benign prostatic hyperplasia (enlarged prostate gland that is not cancerous), the statement noted.

 

For More Mergers and Acquisitions

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.